Bexmarilimab Plus SOC Continues to Elicit Responses in R/R AML and HMA-Refractory MDS
The addition of bexmarilimab to standard-of-care azacitidine or azacitidine plus venetoclax continued to elicit responses in patients with relapsed or refractory acute myeloid leukemia and those with myelodysplastic syndrome who were refractory to hypomethylating agents.
Source: onclive.com